Aaron M Hosios
Overview
Explore the profile of Aaron M Hosios including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Merrick K, Kong Y, Izrael-Tomasevic A, Eng G, Handly E, et al.
Cell Rep Med
. 2024 Oct;
5(10):101778.
PMID: 39378883
5-fluorouracil (5-FU), a major anti-cancer therapeutic, is believed to function primarily by inhibiting thymidylate synthase, depleting deoxythymidine triphosphate (dTTP), and causing DNA damage. Here, we show that clinical combinations of...
2.
Chen J, Merrick K, Kong Y, Izrael-Tomasevic A, Eng G, Handly E, et al.
bioRxiv
. 2023 May;
PMID: 37162991
5-fluorouracil (5-FU) is a successful and broadly used anti-cancer therapeutic. A major mechanism of action of 5-FU is thought to be through thymidylate synthase (TYMS) inhibition resulting in dTTP depletion...
3.
Hosios A, Wilkinson M, McNamara M, Kalafut K, Torrence M, Asara J, et al.
Nat Metab
. 2022 Dec;
4(12):1792-1811.
PMID: 36536136
The mechanistic target of rapamycin complex 1 (mTORC1) senses and relays environmental signals from growth factors and nutrients to metabolic networks and adaptive cellular systems to control the synthesis and...
4.
McNamara M, Hosios A, Torrence M, Zhao T, Fraser C, Wilkinson M, et al.
iScience
. 2022 Nov;
25(11):105458.
PMID: 36388985
mTORC1 is aberrantly activated in cancer and in the genetic tumor syndrome tuberous sclerosis complex (TSC), which is caused by loss-of-function mutations in the TSC complex, a negative regulator of...
5.
Li Z, Ji B, Dixit P, Tchourine K, Lien E, Hosios A, et al.
Nat Metab
. 2022 Jun;
4(6):711-723.
PMID: 35739397
Production of oxidized biomass, which requires regeneration of the cofactor NAD, can be a proliferation bottleneck that is influenced by environmental conditions. However, a comprehensive quantitative understanding of metabolic processes...
6.
Schrotter S, Yuskaitis C, MacArthur M, Mitchell S, Hosios A, Osipovich M, et al.
Cell Rep
. 2022 May;
39(7):110824.
PMID: 35584673
The tuberous sclerosis complex (TSC) 1 and 2 proteins associate with TBC1D7 to form the TSC complex, which is an essential suppressor of mTOR complex 1 (mTORC1), a ubiquitous driver...
7.
Hosios A, Manning B
Cancer Res
. 2021 Oct;
81(19):4896-4898.
PMID: 34598998
The Warburg effect, the propensity of some cells to metabolize glucose to lactate in the presence of oxygen (also known as aerobic glycolysis), has long been observed in cancer and...
8.
Hosios A, Li Z, Lien E, Heiden M
Bio Protoc
. 2021 Jul;
8(11):e2876.
PMID: 34285990
Studying lipid metabolism in cultured cells is complicated by the fact that cells are typically cultured in the presence of animal serum, which contains a wide, variable, and undefined variety...
9.
Keibler M, Dong W, Korthauer K, Hosios A, Moon S, Sullivan L, et al.
FEBS J
. 2021 Apr;
288(19):5629-5649.
PMID: 33811729
Many metabolic phenotypes in cancer cells are also characteristic of proliferating nontransformed mammalian cells, and attempts to distinguish between phenotypes resulting from oncogenic perturbation from those associated with increased proliferation...
10.
Torrence M, MacArthur M, Hosios A, Valvezan A, Asara J, Mitchell J, et al.
Elife
. 2021 Mar;
10.
PMID: 33646118
The mechanistic target of rapamycin complex 1 (mTORC1) stimulates a coordinated anabolic program in response to growth-promoting signals. Paradoxically, recent studies indicate that mTORC1 can activate the transcription factor ATF4...